Compare LOVE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | PHAR |
|---|---|---|
| Founded | 1998 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.2M | 1.2B |
| IPO Year | 2018 | 2020 |
| Metric | LOVE | PHAR |
|---|---|---|
| Price | $15.65 | $12.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $25.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 129.1K | 10.3K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $697,115,000.00 | N/A |
| Revenue This Year | $4.63 | $10.04 |
| Revenue Next Year | $6.40 | $2.51 |
| P/E Ratio | ★ $55.79 | $3,041.22 |
| Revenue Growth | ★ 2.42 | N/A |
| 52 Week Low | $10.33 | $9.54 |
| 52 Week High | $21.06 | $21.34 |
| Indicator | LOVE | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 32.93 |
| Support Level | $14.04 | $11.43 |
| Resistance Level | $16.25 | $17.41 |
| Average True Range (ATR) | 0.62 | 0.50 |
| MACD | -0.13 | -0.18 |
| Stochastic Oscillator | 62.33 | 20.52 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.